Neurotar presentation in the Biomarker category focuses on the ways in which Neurotar’s services aid biomarker developers and highlights cooperation with the Swedish BioChromix AB in the area of biomarker development for Alzheimer’s.
In total, € 0,5 Mil. have been invested into Neurotar by two angel investors during 2010-2012. The investment was used to build up Neurotar’s infrastructure and provide working capital.
The focus of 2012 Symposium was on CNS. The feedback was overwhelmingly positive. In response to the requests of this year’s attendees, next year’s topics will include data analysis and skin imaging.
During a three-day trip, Neurotar’s Katja Karelina and Leonard Khirug visited five pharma and biotech companies in the Zurich area and in Lausanne, and met many more Swiss companies at the Swiss-Scandinavian Bio-Business Seminar. Neurotar also held a presentation at the latter event.
Thanks to our French consultant, Christine Patoux of Hoffren Consultancy, our three day schedule was filled with meetings in Paris, Strasbourgh and Lillie.
Neurotar completes the second round of investment and registers 1200 new shares on 28.12.2012. Thanks to our investors for their endorsement of this year’s results and their confidence in our future potential! The new investment provides us with operating capital necessary to match the growing demand for our services in 2012-2013.
In terms of distance, we have simply moved from one building to the other next door. However, in terms of qualitative change, this move has been very significant. Our new premises include a newly renovated and customized laboratory space and an office with a broad window view of the Viikki library. Our engineer is focused […] Read more »